Prexton Therapeutics

Prexton Therapeutics focuses on developing novel compound drugs for the treatment of central nervous system (CNS) diseases. The company was founded in 2012 by its current CEO, Mr. Francois Conquet, and Merck Ventures. It adopts a completely new scientific approach, fully integrating molecular biology, behavioral science, and chemical technologies to address Parkinson's disease and other brain disorders.